Lupin Limited (LUPIN) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.147x

Based on the latest financial reports, Lupin Limited (LUPIN) has a cash flow conversion efficiency ratio of 0.147x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs29.03 Billion ≈ $313.93 Million USD) by net assets (Rs197.28 Billion ≈ $2.13 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Lupin Limited - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Lupin Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Lupin Limited for a breakdown of total debt and financial obligations.

Lupin Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lupin Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Mowi ASA
OL:MOWI
0.199x
Stanley Black & Decker Inc
NYSE:SWK
0.106x
Healthpeak Properties Inc
NYSE:DOC
0.036x
Washington H Soul Pattinson & Company Ltd
AU:SOL
-0.041x
Metso Oyj
HE:METSO
0.054x
China Development Financial Holding Corp
TW:2883
-0.072x
Hunan Yuneng New Energy Battery Material Co. Ltd. A
SHE:301358
N/A
BorgWarner Inc
NYSE:BWA
0.110x

Annual Cash Flow Conversion Efficiency for Lupin Limited (2004–2025)

The table below shows the annual cash flow conversion efficiency of Lupin Limited from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Lupin Limited.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs172.94 Billion
≈ $1.87 Billion
Rs30.00 Billion
≈ $324.43 Million
0.173x -31.66%
2024-03-31 Rs143.73 Billion
≈ $1.55 Billion
Rs36.48 Billion
≈ $394.56 Million
0.254x +67.83%
2023-03-31 Rs125.43 Billion
≈ $1.36 Billion
Rs18.97 Billion
≈ $205.15 Million
0.151x +403.24%
2022-03-31 Rs122.22 Billion
≈ $1.32 Billion
Rs3.67 Billion
≈ $39.72 Million
0.030x -77.14%
2021-03-31 Rs138.58 Billion
≈ $1.50 Billion
Rs18.22 Billion
≈ $197.02 Million
0.131x +12.60%
2020-03-31 Rs125.81 Billion
≈ $1.36 Billion
Rs14.69 Billion
≈ $158.85 Million
0.117x -3.37%
2019-03-31 Rs137.89 Billion
≈ $1.49 Billion
Rs16.66 Billion
≈ $180.17 Million
0.121x -6.05%
2018-03-31 Rs136.17 Billion
≈ $1.47 Billion
Rs17.51 Billion
≈ $189.38 Million
0.129x -57.69%
2017-03-31 Rs135.32 Billion
≈ $1.46 Billion
Rs41.14 Billion
≈ $444.86 Million
0.304x +1022.36%
2016-03-31 Rs111.95 Billion
≈ $1.21 Billion
Rs-3.69 Billion
≈ $-39.90 Million
-0.033x -110.73%
2015-03-31 Rs88.98 Billion
≈ $962.30 Million
Rs27.33 Billion
≈ $295.57 Million
0.307x +7.27%
2014-03-31 Rs69.99 Billion
≈ $756.86 Million
Rs20.04 Billion
≈ $216.72 Million
0.286x +20.48%
2013-03-31 Rs52.64 Billion
≈ $569.24 Million
Rs12.51 Billion
≈ $135.29 Million
0.238x +73.36%
2012-03-31 Rs40.85 Billion
≈ $441.80 Million
Rs5.60 Billion
≈ $60.57 Million
0.137x -42.67%
2011-03-31 Rs33.33 Billion
≈ $360.41 Million
Rs7.97 Billion
≈ $86.18 Million
0.239x -8.32%
2010-03-31 Rs25.93 Billion
≈ $280.46 Million
Rs6.76 Billion
≈ $73.15 Million
0.261x -20.06%
2009-03-31 Rs14.39 Billion
≈ $155.63 Million
Rs4.70 Billion
≈ $50.78 Million
0.326x +62.70%
2008-03-31 Rs12.89 Billion
≈ $139.41 Million
Rs2.59 Billion
≈ $27.96 Million
0.201x -1.57%
2007-03-31 Rs8.73 Billion
≈ $94.45 Million
Rs1.78 Billion
≈ $19.24 Million
0.204x -8.77%
2006-03-31 Rs5.89 Billion
≈ $63.68 Million
Rs1.32 Billion
≈ $14.22 Million
0.223x +18.37%
2005-03-31 Rs4.91 Billion
≈ $53.05 Million
Rs925.60 Million
≈ $10.01 Million
0.189x -79.18%
2004-03-31 Rs4.32 Billion
≈ $46.67 Million
Rs3.91 Billion
≈ $42.29 Million
0.906x --

About Lupin Limited

NSE:LUPIN India Drug Manufacturers - Specialty & Generic
Market Cap
$11.39 Billion
Rs1.05 Trillion INR
Market Cap Rank
#2022 Global
#80 in India
Share Price
Rs2305.20
Change (1 day)
-0.27%
52-Week Range
Rs1851.80 - Rs2357.30
All Time High
Rs2396.10
About

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutica… Read more